MilliporeSigma announced this week that it would be increasing its manufacturing capacity in France by 2,700 square-meters.
The U.S. life sciences business of Germany-based Merck KGaA said that the new facility will help expand its CTDMO capabilities, providing a global supply of commercial drug substances, including mAbs and other recombinant proteins, from an integrated site featuring state-of-the-art single-use equipment and onsite regulatory, quality and technical experts. In its recent statement, the company shared that one of the clients that will be supported by the expansion is Y-mAbs Therapeutics.
The Martillac facility will help the biopharma with end-to-end process development and GMP manufacturing services for brain cancer drugs for pediatric patients “in roughly half the time than the approximate 12 years it takes to bring a biologic to the market,” according to Y-mAbs.
According to Millipore, the site is designed to operate “at the highest level of efficiency” and can pivot rapidly between 200 and 2000 liters of drug substance. The site also features two 2000-liter bioreactors in one manufacturing suite.